How can an RNA be used to treat myotonic dystrophy? ARTHEx biotech is focused on the development of the next generation of RNA therapies for genetic diseases. Our first product in the pipeline is a first-in-class treatment against myotonic dystrophy type 1, an orphan and rare disease. This therapy is based on an antisense oligonucleotide that inhibits the action of microRNAs (also known as antimiR). Learn more now: | Sci Ani